Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00232583
Status:
COMPLETED
Last Update Posted:
2017-12-14
First Post:
2005-09-30
Brief Title:
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
Sponsor:
University of Texas Southwestern Medical Center
Organization:
University of Texas Southwestern Medical Center
Study Overview
Official Title:
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2017-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens insulin and metformin versus glyburide metformin and pioglitazone
Detailed Description:
This is a 72 months long randomized clinical trial longitudinally evaluating beta-cell function as well as glycemic control and inflammatory markers in newly diagnosed type 2 diabetic patients on two different treatment regimens insulin and metformin versus glyburide metformin and pioglitazone
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None